What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Breast cancer
Lisa A. Carey spends much of her time researching Breast cancer, Internal medicine, Oncology, Cancer and Cancer research.
The various areas that Lisa A. Carey examines in her Breast cancer study include Gene expression profiling, Epidermal growth factor receptor and Pathology.
Her work on Internal medicine is being expanded to include thematically relevant topics such as MEDLINE.
Her studies in Oncology integrate themes in fields like Neoadjuvant therapy, Chemotherapy, Trastuzumab, Metastatic breast cancer and Metastasis.
Her Cancer research is multidisciplinary, incorporating elements of Guideline, Gynecology and Psychiatry.
Her biological study spans a wide range of topics, including Neoplasm, Microarray, Disseminated cancer and Drug resistance.
Her most cited work include:
- Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. (2910 citations)
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes (1534 citations)
- The molecular portraits of breast tumors are conserved across microarray platforms (1157 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy.
Her Breast cancer study incorporates themes from Clinical trial, Disease and Gynecology.
Her Internal medicine study frequently draws connections to adjacent fields such as Surgery.
Her work carried out in the field of Oncology brings together such families of science as Phases of clinical research, Paclitaxel, Pathology, Lapatinib and Bevacizumab.
Her Cancer research incorporates elements of Cancer research and Confidence interval.
Her research integrates issues of Adjuvant and Anthracycline in her study of Chemotherapy.
She most often published in these fields:
- Breast cancer (75.78%)
- Internal medicine (71.09%)
- Oncology (63.80%)
What were the highlights of her more recent work (between 2019-2021)?
- Internal medicine (71.09%)
- Breast cancer (75.78%)
- Oncology (63.80%)
In recent papers she was focusing on the following fields of study:
Her main research concerns Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy.
Lisa A. Carey is interested in Estrogen receptor, which is a field of Breast cancer.
The concepts of her Oncology study are interwoven with issues in Previously treated, Neoadjuvant therapy, Receptor, Biomarker and Triple-negative breast cancer.
Her Neoadjuvant therapy research incorporates themes from Odds ratio, Meta-analysis and Genomic Biomarker.
Lisa A. Carey has included themes like Mutation and Gerontology in her Cancer study.
Lisa A. Carey combines subjects such as Endocrine therapy, Discontinuation and Anthracycline with her study of Chemotherapy.
Between 2019 and 2021, her most popular works were:
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (196 citations)
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. (93 citations)
- Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial (52 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Lisa A. Carey mainly focuses on Internal medicine, Oncology, Breast cancer, Chemotherapy and Estrogen receptor.
Her Internal medicine study is mostly concerned with Receptor, Triple-negative breast cancer, Previously treated, Trastuzumab and Capecitabine.
She has researched Trastuzumab in several fields, including Metastatic breast cancer and Randomized controlled trial.
Her Oncology study frequently draws connections to other fields, such as HER2 Positive Breast Cancer.
Her Breast cancer research is multidisciplinary, relying on both Biomarker, Guideline and Clinical trial.
Her studies deal with areas such as Immunohistochemistry, HER2 negative, Endocrine system, Stage ii and Locally advanced as well as Estrogen receptor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
